IP Library Granted Patent US 10,875,868
Granted Patent B2
US 10,875,868 · App. 16/700,160 · Granted Dec 29, 2020

Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists

Inventors: Samantha Jane Bamford (Winnersh, GB); Roger John Gillespie (Winnersh, GB); Richard Simon Todd (Winnersh, GB)
Assignee: VERNALIS (R&D) LIMITED
C07D487/04A61K31/197A61K31/519A61K45/06C07D405/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,875,868
App. No.
16/700,160
Granted
Dec 29, 2020
Kind
B2
Abstract

Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.

Claims (3)

1. A compound of formula

2. The compound of claim 1 , wherein the compound is

3. A composition comprising the compound of claim 1 .

Assignments (2)
CHANGE OF NAME Recorded Jan 24, 2022
From: VERNALIS DEVELOPMENT LIMITED
To: LIGAND UK DEVELOPMENT LIMITED
Reel/Frame 058738/0271 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2022
From: VERNALIS (R&D) LIMITED
To: VERNALIS DEVELOPMENT LIMITED
Reel/Frame 058822/0570 →
Priority Claims (1)
GB 0906579.8 · Apr 16, 2009 · national
Continuity (8)
Division 16132411 · Sep 15, 2018
Division 15682346 · Aug 21, 2017
Division 15172126 · Jun 2, 2016
Continuation 14618829 · Feb 10, 2015
Continuation 13889921 · May 8, 2013
Division 12997721
Provisional Application 61075538 · Jun 25, 2008
Related Publication 20200172547A1 · Jun 4, 2020